Health
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Johnson & Johnson (NYSE: JNJ) today announced that nipocalimaba was granted U.S. Food and Drug Administration (FDA) Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE), a debilitating autoantibody-driven disease that impacts approximately 3 to 5 million people worldwide.1 The U.S. FDA's Fast Track designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aimi
About this update from Johnson & Johnson
[{"type":"text","content":"Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing ","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage ","length":179,"tagName":"p","attribs":{}},{"type":"text","content":"Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"SPRING HOUSE, Pa., March 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that nipocalimaba was granted U.S. Food and Drug Administration (FDA) Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE), a debilitating autoantibody-driven disease that impacts approximately 3 to 5 million people worldwide.1 The U.S. FDA's Fast Track designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas, like SLE, where unmet needs remain.2","length":725,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jIgvao1bUyQtFqwMNBmckA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9","width":400,"height":37}},"href":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Nipocalimab earning its fifth FDA Fast Track designat...